Showing results (211-220 of 294) with videos related to
Sort By:
Pageof 30
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 25, 2022
Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR TrialsVincent Wai-Sun Wong, Won Young Tak, George Boon Bee Goh, et al.Plos One|February 29, 2024
Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical informationMatthew McTeer, Douglas Applegate, Peter Mesenbrink, et al.Cancers|April 3, 2021
A <i>PDCD1</i> Role in the Genetic Predisposition to NAFLD-HCC?Nardeen Eldafashi, Rebecca Darlay, Ruchi Shukla, et al.The Lancet. Gastroenterology & Hepatology|August 9, 2020
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation studyStephen A Harrison, Vlad Ratziu, Jérôme Boursier, et al.The American Journal of Gastroenterology|May 27, 2020
Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver DiseaseRamy Younes, Olivier Govaere, Salvatore Petta, et al.Nature Medicine|July 21, 2025
Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitisMaximilian Jara, Jenny Norlin, Mette Skalshøi Kjær, et al.Canadian Liver Journal|August 22, 2022
Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH)Giada Sebastiani, Keyur Patel, Vlad Ratziu, et al.Journal of Hepatology|May 15, 2021
Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysisEmmanuel Anandraj Selvaraj, Ferenc Emil Mózes, Arjun Narayan Ajmer Jayaswal, et al.Hepatology Communications|April 12, 2022
Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanismsChristian A Hudert, Leon A Adams, Anna Alisi, et al.Hepatology (Baltimore, Md.)|March 25, 2022
Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity scoreRish K Pai, Vipul Jairath, Malcolm Hogan, et al.Pageof 30